- Home
- NVVE vs KLTO Comparison
NVVE vs KLTO Comparison
Compare NVVE & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVVE
- KLTO
- Stock Information
- Founded
- NVVE 1996
- KLTO 2019
- Country
- NVVE United States
- KLTO United States
- Employees
- NVVE N/A
- KLTO N/A
- Industry
- NVVE Oil Refining/Marketing
- KLTO
- Sector
- NVVE Energy
- KLTO
- Exchange
- NVVE Nasdaq
- KLTO NYSE
- Market Cap
- NVVE 5.5M
- KLTO 5.9M
- IPO Year
- NVVE N/A
- KLTO N/A
- Fundamental
- Price
- NVVE $0.95
- KLTO $1.34
- Analyst Decision
- NVVE
- KLTO
- Analyst Count
- NVVE 0
- KLTO 0
- Target Price
- NVVE N/A
- KLTO N/A
- AVG Volume (30 Days)
- NVVE 1.8M
- KLTO 22.5M
- Earning Date
- NVVE 08-12-2025
- KLTO 08-15-2025
- Dividend Yield
- NVVE N/A
- KLTO N/A
- EPS Growth
- NVVE N/A
- KLTO N/A
- EPS
- NVVE N/A
- KLTO N/A
- Revenue
- NVVE $5,440,777.00
- KLTO N/A
- Revenue This Year
- NVVE $892.33
- KLTO N/A
- Revenue Next Year
- NVVE N/A
- KLTO N/A
- P/E Ratio
- NVVE N/A
- KLTO N/A
- Revenue Growth
- NVVE N/A
- KLTO N/A
- 52 Week Low
- NVVE $0.82
- KLTO $0.11
- 52 Week High
- NVVE $8.80
- KLTO $3.91
- Technical
- Relative Strength Index (RSI)
- NVVE 50.97
- KLTO N/A
- Support Level
- NVVE $0.92
- KLTO N/A
- Resistance Level
- NVVE $1.13
- KLTO N/A
- Average True Range (ATR)
- NVVE 0.10
- KLTO 0.00
- MACD
- NVVE 0.01
- KLTO 0.00
- Stochastic Oscillator
- NVVE 86.67
- KLTO 0.00
About NVVE Nuvve Holding Corp.
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.